AI Article Synopsis

  • Triple negative breast cancer (TNBC) often recurs after treatment, particularly in those with residual disease post-chemotherapy, and capecitabine is commonly used as a follow-up treatment for these patients.! -
  • A study analyzed 170 TNBC patients who received capecitabine after neoadjuvant chemotherapy, finding a 30% recurrence rate and 18% death rate, with a 3-year disease-free survival (DFS) of 66% and overall survival (OS) of 74% in the cohort.! -
  • Results indicated that while capecitabine's effectiveness was lower than past studies, certain patients, especially those with specific residual disease characteristics, could still benefit from it,

Article Abstract

Background: Triple negative breast cancer (TNBC) is characterized by high rates of recurrence, especially in patients with residual disease after neoadjuvant chemotherapy (NAC). Capecitabine is being used as standard adjuvant treatment in residual TNBC. We aimed to investigate the real-life data regarding the efficacy of capecitabine in residual TNBC.

Design And Methods: In this retrospective multicenter study, TNBC patients with residual disease were evaluated. Patients, who received standard anthracycline and taxane-based NAC and adjuvant capecitabine were eligible. Overall survival (OS), disease free survival (DFS) and toxicity were analyzed.

Results: 170 TNBC patients with residual disease were included. Of these, 62.9% were premenopausal. At the time of analysis, the recurrence rate was 30% and death rate was 18%. The 3-year DFS and OS were 66% and 74%, respectively. In patients treated with adjuvant capecitabine, residual node positive disease stood out as an independent predictor of DFS ( = 0.024) and OS ( = 0.032). Undergoing mastectomy and the presence of T2 residual tumor was independent predictors of DFS ( = 0.016) and OS ( = 0.006), respectively.

Conclusion: The efficacy of capecitabine was found lower compared to previous studies. Selected patients may have further benefit from addition of capecitabine. The toxicity associated with capecitabine was found lower than anticipated.

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2024.2337261DOI Listing

Publication Analysis

Top Keywords

adjuvant capecitabine
12
capecitabine residual
12
patients residual
12
residual disease
12
capecitabine
8
residual
8
triple negative
8
negative breast
8
breast cancer
8
efficacy capecitabine
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!